gvs 111 has been researched along with muramidase in 1 studies
| Studies (gvs 111) | Trials (gvs 111) | Recent Studies (post-2010) (gvs 111) | Studies (muramidase) | Trials (muramidase) | Recent Studies (post-2010) (muramidase) |
|---|---|---|---|---|---|
| 91 | 2 | 31 | 23,777 | 207 | 5,249 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bobkova, NA; Gruden, MA; Gudasheva, TA; Morozova-Roche, LA; Noppe, W; Ostrovskaya, RU; Samokhin, AN; Seredinin, SB; Sewell, RD; Sherstnev, VV | 1 |
1 other study(ies) available for gvs 111 and muramidase
| Article | Year |
|---|---|
The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Autoantibodies; Behavior, Animal; Dipeptides; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Male; Memory; Mice; Microscopy, Atomic Force; Muramidase; Nerve Growth Factors; Neuroprotective Agents; Nootropic Agents; Olfactory Bulb; Peptide Fragments; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Space Perception; Time Factors | 2007 |